GE drawn to radiopharma boom with strategic buy

5 December 2024

GE Healthcare (Nasdaq: GEHC) has announced plans to acquire from Sumitomo Chemical (TYO: 4005) the half of Nihon Medi-Physics (NMP) that it doesn’t own.

Securing full ownership of the Tokyo-based radiopharmaceutical company, a process that is due to complete early next year, will help GE capitalize on rapidly growing interest in this treatment modality.

Chief executive Peter Arduini has previously identified radiopharmaceuticals, artificial intelligence, and new products as key growth drivers for the company over the next three years, particularly in regions where precision medicine adoption is accelerating.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK